This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Terachi, T. Articles by Caulfield, M. J. Search for Related Content PubMed PubMed Citation Articles by Terachi, T. Articles by Caulfield, M. J.

Coexistence of Autologous Antibodies and Decay-accelerating Factor, an Inhibitor of Complement, on Human Renal Tumor Cells

Section of Immunology, Research Institute of the Cleveland Clinic [T. T., M. J. C.] and the Department of Urology, Cleveland Clinic Foundation [T. T., J. E. P.] Cleveland, Ohio 44195; and the Institute of Pathology, Case Western Reserve University [M. E. M.], Cleveland, Ohio 44106

Autologous immunoglobulin was detected on the cell surface of tumor cells freshly isolated from cancerous kidneys of patients with renal cell carcinoma by flow cytometry after staining with murine anti-human IgG monoclonal antibodies. Cells isolated in parallel from macroscopically normal regions of the tumorous kidneys were not specifically stained with the anti-human IgG reagents. In further studies, tumor cells were stained with an antibody to decay-accelerating factor (DAF), a known inhibitor of complement. Flow cytometry of these cells revealed that nearly all tumor cells expressed DAF, and that the intensity of staining with the anti-DAF monoclonal antibody correlated with the staining of cells with anti-IgG. The results suggest that tumor cells coated with autologous antibody may be resistant to complement-mediated cytotoxicity in vivo through the expression of high levels of DAF.

¹ Present address: Department of Urology, Kyoto University Hospital, Kyoto 606, Japan.

² Present address: Department of Urology, Wayne State University, Detroit, MI 48201.

³ To whom requests for reprints should be addressed, at Section of Immunology, Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.

Received 12/ 3/90. Accepted 3/ 1/91.

This article has been cited by other articles:

				R. Ohta, N. Kondor, N. Dohi, S. Tomlinson, M. Imai, V. M. Holers, H. Okada, and N. Okada Mouse Complement Receptor-Related Gene y/p65-Neutralized Tumor Vaccine Induces Antitumor Activity In Vivo J. Immunol., July 1, 2004; 173(1): 205 - 213. [Abstract] [Full Text] [PDF]